Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Disulfiram + copper is a combination therapy under investigation primarily for cancer treatment. Disulfiram, a thiocarbamate derivative long approved for alcoholism, acts as a metal chelator and forms complexes with copper ions. When combined with copper (often as copper gluconate), the resulting complex exhibits potent anticancer activity in preclinical models and early clinical trials. The mechanism of action involves inhibition of aldehyde dehydrogenase, proteasome inhibition, stimulation of reactive oxygen species (ROS) production, and induction of cell death pathways selectively in cancer cells—especially those with elevated intracellular copper levels. The active metabolite diethyldithiocarbamate (DDC) forms a cytotoxic complex with Cu(II), which can penetrate tumor cells and induce apoptosis via oxidative stress and other mechanisms. This combination is being repurposed for oncology indications such as glioblastoma, pancreatic cancer, prostate cancer, among others[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disulfiram + copper.